WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL RESEARCH

Review Article

Coden USA: WJPPCL

2026
Volume: 03
Issue: 05
Page: 32-46

ROLE OF LEVODOPA AND CARBIDOPA IN PARKINSON'S DISEASE TREATMENT: THEIR DRUG DELIVERY APPROACHES

B. Pranusha and Bhargav Eranti*

Department of Pharmaceutics, Raghavendra Institute of Pharmaceutical Education and Research, Anantapur.

Received: 18 February 2026 **Revised: 10 March 2026** **Accepted: 31 March 2026**

Corresponding Author: Bhargav Eranti

Address: Department of Pharmaceutics, Raghavendra Institute of Pharmaceutical Education and Research, Anantapur. **DOI:** https://doi.org/10.5281/zenodo.19940483,

ABSTRACT

Parkinson's disease (PD) is a progressive neurodegenerative disorder marked by dopaminergic neuron loss. Levodopa, the primary treatment, is commonly paired with carbidopa to enhance brain bioavailability and minimize peripheral side effects. However, challenges such as motor fluctuations and limited absorption necessitate advanced drug delivery approaches. These include extended-release, gastro-retentive, and transdermal systems, as well as innovative formulations like the Accordion Pill®, DM-1992, and subcutaneous infusions like ND0612. Such strategies aim to provide sustained plasma levels, reduce dosing frequency, and improve patient compliance and therapeutic outcomes. Ongoing research is vital for optimizing delivery and enhancing the quality of life in PD management. Innovative drug delivery systems for levodopa/carbidopa in Parkinson's disease aim to overcome motor fluctuations and improve patient outcomes. Approaches include 3D-printed scaffolds, inhalable powders, enteral suspensions, segmented tablets, and extended-release formulations, offering controlled and personalized therapy. These strategies enhance bioavailability, stability, and symptom management in advanced PD care. Advanced strategies in Levodopa delivery for Parkinson's disease include PEGylation, lipid nanoparticle conjugation, and ligand-mediated targeting for enhanced brain penetration. Functionalized nanoparticles improve bioavailability, reduce side effects, and offer controlled release. Clinical trials like ELLDOPA, STRIDE-PD, and CALM-PD guide optimized therapy, shaping future personalized treatment approaches.

KEYWORDS: Parkinson's disease (PD), drug delivery approaches, clinical trials.

INTRODUCTION

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra, leading to motor symptoms such as bradykinesia, rigidity, and tremors.[1] Levodopa remains the gold standard treatment for managing PD symptoms due to its efficacy in replenishing central dopamine levels. However, when administered alone, a significant portion of levodopa is metabolized peripherally, resulting in reduced central availability and adverse effects such as nausea and cardiovascular complications. To enhance therapeutic outcomes, levodopa is commonly combined with carbidopa, a peripheral decarboxylase inhibitor that prevents the premature conversion of levodopa to dopamine outside the central nervous system.[2] This combination increases the amount of levodopa reaching the brain, allowing for lower dosing and minimizing peripheral side effects.[4] Despite its effectiveness, long-term use of levodopa-carbidopa therapy is associated with motor fluctuations and dyskinesia, prompting ongoing research into optimized dosing strategies and adjunctive therapies. Understanding the pharmacokinetics and clinical implications of levodopa and carbidopa combination therapy is essential for improving management strategies and patient quality of life in PD.[3]

Levodopa, a precursor of dopamine, is often combined with Carbidopa, a peripheral decarboxylase inhibitor, to enhance its therapeutic effect for Parkinson's disease. Chemically, Levodopa is an aromatic amino acid, while Carbidopa (CD) is a hydrazine derivative. The combination stabilizes Levodopa by preventing its premature conversion to dopamine outside the brain, allowing more to reach the central nervous system. Physically, both are crystalline solids that are soluble in water, and their combination is commonly formulated as oral tablets.

Drug Delivery Approaches

i. Oral Drug delivery approach to for Levodopa or Carbidopa

Oral drug delivery, particularly for Parkinson's disease medications like levodopa and carbidopa, presents challenges like variable absorption rates and gastrointestinal issues. Advanced formulations like extended-release, gastric-retention, and transdermal systems aim to improve patient outcomes by providing stable drug levels and reducing motor complications.

a. Extended release formulation

Extended-release, gastric-retention, and transdermal systems offer alternatives to immediate-release formulations for Parkinson's disease treatment. These systems provide stable plasma drug levels, reduce dosing frequency, and reduce motor fluctuations, like IPX066, a promising clinical trial.

IPX066 is a new extended-release LD/CD capsule with a combination of immediate and sustained-release pellets. It has a similar tmax but a greater AUC. Its bioavailability is 75% of immediate-release LD/CD. Two randomized controlled trials compared IPX066 with immediate-release LD/CD in Parkinson's disease patients with motor fluctuations. Other therapeutic strategies include XP21279 and the 'accordion pill', which improve drug absorption and sustained delivery. A pilot study showed significant reductions in total daily OFF time.[4]

b. Gastro retentive drug delivery system

Gastro-retentive delivery systems for levodopa and carbidopa offer significant advantages in the management of Parkinson's disease. By providing more stable plasma drug levels, reducing dosing frequency, and minimizing motor complications, these formulations can greatly enhance the therapeutic outcomes and quality of life for patients.

The Accordion Pill® is an innovative gastric-retention system developed by Intec Pharma, characterized by its multilayer film technology. This system facilitates multiple drug release profiles and supports fixed-dose combinations. Phase II clinical studies have demonstrated that the Accordion Pill® achieves effective gastric retention and improves pharmacokinetics (PK) and therapeutic efficacy for various drugs, including those with narrow absorption windows and poor solubility. The Accordion Pill® formulation of carbidopa/levodopa comprises five layers, resulting in stable plasma concentrations. Noteworthy clinical achievements include MRI evidence showing that the Accordion Pill® can remain in the stomach for over 8 hours.[5]

bi. Gastroretentive Levodopa Preparation (DM-1992):

DM-1992 is a novel gastroretentive Levodopa formulation engineered for extended-release and twice-daily dosing. It consists of a dual-layer tablet, with an immediate-release layer and a gastroretentive extended-release core containing carbidopa/levodopa. The tablet swells upon contact with gastric secretions, ensuring prolonged stomach retention and stable plasma

concentrations over several hours. DM-1992 must be taken with food to optimize gastroretention, offering improved symptom control and patient compliance in PD management.[6]

c. Controlled release formulations

Controlled release formulations of levodopa/carbidopa are crucial in Parkinson's disease management, providing stable plasma levels, reduced dosing frequency, improved motor performance, and enhanced quality of life.

ci. Multi-drug loaded microcapsules

A new multi-drug delivery system using microcapsules for controlled Parkinson's disease (PD) drug release has been developed. The system, made from poly-L-lactide (PLLA) and poly(caprolactone) (PCL), aims to deliver three drugs simultaneously, including levodopa (LD), carbidopa (CD), and entacapone (ENT), reducing dosing frequency and enhancing patient compliance. The microcapsules are hollow and made using a double-emulsion solvent evaporation method. The hydrophobic ENT release has a slower rate than the hydrophilic LD and CD. The microcapsules are designed to float in gastric fluids, ensuring sustained drug release. The PLLA/PCL ratio influences buoyancy and degradation. The system could be further developed for in vivo evaluation as a more effective drug delivery system for PD.[7]

ii. Transdermal drug delivery

Transdermal drug delivery systems (TDDS) offer a promising alternative for the administration of drugs like levodopa and carbidopa, which are commonly used in thetreatment of Parkinson's disease (PD). These systems provide several advantages over traditional oral administration, including improved drug stability, controlled release, and enhanced patient compliance.

a. Levodopa Stability and Delivery with β-Cyclodextrin Transdermal Patches:

Levodopa, when complexed with β-cyclodextrin in transdermal patches, shows enhanced stability. This is crucial as levodopa has a short plasma half-life and a narrow absorption window in the small intestine. The use of polymers like xanthan gum and Carbopol 971 in the patches ensures uniformity and controlled drug release over a 6-hour period, with carbopol patches showing increased permeation and optimal stability.[8]

ai. ND0701 Apomorphine Patch Pump Technology

ND0701, a different concentrated apomorphine formulation, was tested via patch pump technology on healthy participants. This concentrated apomorphine solution has a lower acidity and causes negligible to moderate localized skin responses. This treatment is not yet approved for clinical usage, but it might be a viable one in the future.[9]

aii. Subcutaneous delivery with NDO612

Transdermal drug delivery systems (TDDS) have evolved as a means to provide steady and controlled release of medications, thereby enhancing therapeutic outcomes and patient compliance. While traditional TDDS typically involve patches that deliver drugs across the skin barrier, advancements in this field have extended to subcutaneous delivery methods, such as the ND0612 system for Parkinson's disease (PD). ND0612 represents a significant innovation in continuous drug delivery, addressing the limitations of oral levodopa administration, which often leads to motor fluctuations due to its short half-life and variable absorption. Unlike conventional TDDS, which may struggle with the delivery of large molecules or drugs requiring precise blood concentration levels, ND0612 leverages subcutaneous infusion to maintain stable plasma levels of levodopa. This method aligns with the goals of TDDS by providing a non-invasive, continuous drug administration route, thereby minimizing the peaks and troughs associated with oral dosing. The clinical outcomes observed in the study by Olanow et al. underscore the potential of subcutaneous delivery systems as a therapeutic strategy within the TDDS framework. Patients receiving ND0612 showed a marked reduction in OFF time and increased ON time, highlighting the system's efficacy in providing continuous dopaminergic stimulation. Despite some challenges, such as infusion site reactions, ND0612 exemplifies the advances in TDDS aimed at improving drug delivery for chronic conditions like PD.

iii. Nanoparticles for Enhanced Drug Delivery:

Nanoparticles, including polymeric and PEGylated polycaprolactone-based nanoparticles, have shown promise in improving drug stability, bioavailability, and BBB penetration, thereby enhancing the delivery of drugs like monoamine oxidase-B inhibitors and dopamine.

a. 3D-Printed PLA/CS Scaffolds for Controlled Levodopa Delivery in Parkinson's Disease

Parkinson's disease, marked by dopamine deficiency, is primarily treated with Levodopa. This study developed 3D-printed polylactic acid (PLA) and chitosan (CS) scaffolds for

controlled Levodopa release. Characterized by SEM with pore sizes of 100-200 µm, these scaffolds demonstrated enhanced swelling and weight loss with maintained mechanical strength. Levodopa was released over 14 days, following Fickian diffusion and kinetic models. Biocompatibility was confirmed via MTT assays and fluorescence microscopy using hAD-MSCs, showing no toxicity and successful cell integration. PLA/CS scaffolds present a promising platform for controlled Levodopa delivery and potential neural tissue engineering applications.[10]

b. Marketed Dosage Forms

bi. Inhalation Powder (Inbrija)

Inbrija is an inhaled formulation of levodopa designed to provide rapid relief from OFF periods in patients with Parkinson's disease. OFF periods occur when the effects of oral levodopa diminish, leading to the reappearance of motor symptoms. Inbrija is intended as an adjunct to standard oral carbidopa-levodopa therapy, not as a replacement.

The inhalation route bypasses the gastrointestinal tract, allowing levodopa to be absorbed directly through the lungs for faster action. This results in a quicker onset of symptom relief, typically within 10 minutes. Inbrija can be used up to five times per day as needed, providing flexible management of sudden OFF episodes. Clinical studies have shown that Inbrija significantly improves motor function and reduces time spent in the OFF state compared to placebo. Additionally, this method of administration reduces gastrointestinal side effects associated with oral levodopa, offering a targeted and effective therapeutic option for managing Parkinson's disease symptoms.

bii. Enteral Suspension (Duopa) for Continuous Levodopa-Carbidopa Delivery in Parkinson's Disease

Duopa is an enteral suspension formulation of levodopa and carbidopa, designed for continuous 16-hour delivery in patients with advanced Parkinson’s disease (PD). Administered through a percutaneous endoscopic gastrostomy with jejunal extension (PEG-J), Duopa bypasses the stomach, ensuring steady and consistent levodopa absorption. This helps in minimizing motor fluctuations, including OFF periods and dyskinesia, which are common with oral dosing.

Clinical trials demonstrate that Duopa significantly reduces OFF time while increasing ON time without troublesome dyskinesia, making it particularly beneficial for PD patients with

severe motor fluctuations. The formulation allows for individualized, adjustable dosing to optimize symptom control. While highly effective, Duopa requires a surgical procedure for tube placement, and its use necessitates regular patient monitoring due to the complexity of the device. Despite these challenges, Duopa offers a valuable solution for long-term management of advanced PD symptoms.

biii. Dhivy Segmented Tablets: Flexible Dosing for Parkinson's Disease Management

Dhivy is a segmented tablet specifically designed to provide customizable dosing of carbidopa and levodopa, widely used in the treatment of Parkinson's disease. Each tablet can be divided into quarters, offering the following dose increments:

- ¼ Dhivy pill: 6.25 mg carbidopa/25 mg levodopa
- ½ Dhivy pill: 12.5 mg carbidopa/50 mg levodopa
- ¾ Dhivy pill: 18.75 mg carbidopa/75 mg levodopa
- Whole Dhivy pill: 25 mg carbidopa/100 mg levodopa

This design allows patients to precisely adjust their dosing based on individual symptom control needs, which is crucial in managing the fluctuating motor symptoms associated with Parkinson's disease. The incremental dosing enables fine-tuning of levodopa administration, helping to minimize motor complications such as dyskinesia while improving the overall efficacy of therapy. Dhivy enhances patient adherence by offering a convenient and adaptable approach to medication administration, aligned with the principles of personalized medicine.

c. Other Formulations with Levodopa: Stalevo

Stalevo is an advanced formulation combining carbidopa, levodopa, and entacapone, a catechol-O-methyltransferase (COMT) inhibitor, designed to enhance the efficacy and duration of levodopa therapy in Parkinson's disease. This combination therapy addresses motor fluctuations and extends the therapeutic effects of levodopa by inhibiting its peripheral metabolism. Stalevo is available in several strengths: 12.5 mg carbidopa/50 mg levodopa/200 mg entacapone, 18.75 mg carbidopa/75 mg levodopa/200 mg entacapone, and 25 mg carbidopa/100 mg levodopa/200 mg entacapone, with higher doses also available. Entacapone's inclusion prolongs levodopa's half-life, reducing the frequency of dosing and improving symptom control. Clinical studies have shown that Stalevo significantly decreases OFF time and increases ON time compared to carbidopa-levodopa alone, making it a valuable treatment option for patients with significant motor fluctuation.

d. PRODOPA: 24-Hour Subcutaneous Infusion of Levodopa/Carbidopa for Severe Motor Fluctuations

PRODOPA is a groundbreaking treatment for severe motor fluctuations in Parkinson's disease, administered as a 24-hour subcutaneous infusion of levodopa and carbidopa. This continuous infusion system is designed for patients who have inadequate control with oral medications. PRODOPA provides a steady and controlled delivery of levodopa, resulting in consistent plasma levels and minimizing the motor fluctuations commonly associated with oral dosing regimens. Clinical studies have shown that PRODOPA significantly reduces OFF time and increases ON time with minimal dyskinesia compared to traditional oral therapies. It allows for precise dosing adjustments to meet individual patient needs, enhancing motor function and overall quality of life. Despite its benefits, PRODOPA requires careful management and patient education to ensure optimal use and to address potential complications associated with the infusion device.

e. Crexont: Longer-Acting Levodopa/Carbidopa Pill for Parkinson's disease

Crexont is an extended-release formulation of levodopa and carbidopa designed to offer prolonged symptom control in Parkinson's disease. This longer-acting pill utilizes advanced matrix technology to release levodopa and carbidopa over an extended period, providing more consistent plasma levels and reducing the frequency of dosing compared to immediate-release formulations. Clinical studies have shown that Crexont effectively decreases OFF time and enhances ON time while offering a stable therapeutic response throughout the day. By extending the duration of action, Crexont addresses dosing challenges, potentially improving patient adherence and quality of life. However, its extended-release nature requires careful management to balance efficacy with the risk of side effects, such as dyskinesia and other levodopa-related adverse events.

f. Controlled-Release Tablets (Sinemet CR) for Parkinson's disease

Sinemet CR is a controlled-release formulation of levodopa and carbidopa designed to offer extended symptom control for Parkinson's disease. Utilizing a matrix-based delivery system, Sinemet CR releases levodopa gradually over an extended period, resulting in more stable plasma levels and reducing the need for frequent dosing. This prolonged action helps to maintain consistent motor control and mitigate fluctuations in symptoms.

Clinical studies have demonstrated that Sinemet CR effectively reduces OFF time and increases ON time compared to immediate-release levodopa formulations, with fewer peaks

and troughs in symptom control. While the controlled-release profile improves patient adherence and quality of life by managing symptoms more consistently, careful dosage adjustment is necessary to balance efficacy with potential side effects such as dyskinesia or motor fluctuations.

iv. Surface Modification or Conjugation for Targeting

Surface modifications of Levodopa using PEGylation and nanoparticle systems have been widely explored for enhancing drug delivery to the brain. For example, PEGylated Levodopa nanoparticles have demonstrated prolonged circulation time and improved brain bioavailability in preclinical studies. In another case, Levodopa-loaded solid lipid nanoparticles showed enhanced brain uptake via the enhanced permeability and retention (EPR) effect, which allows nanoparticles to passively accumulate in areas with disrupted vasculature, such as the blood-brain barrier (BBB). Mechanistically, the EPR effect leverages the leaky vasculature of the BBB, allowing nano-sized particles to enter the brain more effectively. Surface conjugation using ligands like transferrin further enhances active targeting by interacting with specific receptors on BBB endothelial cells. Future research focuses on receptor-mediated delivery systems and ligand-targeted nanoparticles that offer precise targeting of dopaminergic neurons. These advanced systems hold promise for improving therapeutic outcomes and minimizing side effects in Parkinson's disease patients.[11]

a. Surface Functionalization and Levodopa Brain Delivery

Surface functionalization of Levodopa nanoparticles is a cutting-edge strategy to improve brain delivery by overcoming the blood-brain barrier (BBB). Functionalizing the surface of Levodopa-loaded nanoparticles with ligands, such as transferrin or lactoferrin, enables active targeting of receptors expressed on BBB endothelial cells, allowing receptor-mediated transcytosis. These ligand-functionalized nanoparticles have demonstrated increased brain penetration and selective delivery to dopaminergic neurons. Transferrin-functionalized Levodopa nanoparticles have shown enhanced transport across the BBB by interacting with transferrin receptors, which are overexpressed on the BBB in Parkinson's disease patients. Similarly, lactoferrin-functionalized nanoparticles improve targeting efficiency and reduce peripheral side effects. Mechanistically, these functionalized nanoparticles bind to receptors on the BBB, facilitating uptake through endocytosis. This targeted delivery ensures higher concentrations of Levodopa reach the brain, improving therapeutic outcomes and minimizing

systemic exposure. Current research is focused on developing multifunctionalized nanoparticles to simultaneously target multiple BBB receptors for even more efficient drug delivery.

b. Levodopa and Lipid Nanoparticle Conjugation

The conjugation of Levodopa with lipid nanoparticles presents a promising strategy for improving brain delivery in Parkinson's disease treatment. Lipid nanoparticles, such as solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), provide a biocompatible and stable delivery platform for Levodopa. These systems enhance drug bioavailability, protect it from premature degradation, and allow for sustained release, reducing the required dosing frequency and minimizing side effects. Lipid conjugation increases the lipophilicity of Levodopa, improving its ability to cross the blood-brain barrier (BBB). Lipid nanoparticles can also leverage the enhanced permeability and retention (EPR) effect, enabling passive targeting and accumulation in brain tissues. Mechanistically, lipid-based carriers facilitate improved encapsulation, stability, and controlled release kinetics-critical factors for neurodegenerative disease therapies. Recent studies demonstrate that Levodopa lipid nanoparticle conjugation enhances therapeutic outcomes by extending circulation time and improving brain-targeting efficiency.[12-13]

c. PEGylation and Levodopa Targeting

PEGylation, the attachment of polyethylene glycol (PEG) chains to Levodopa, significantly enhances its pharmacokinetic profile and targeting efficiency for brain delivery in Parkinson's disease. By increasing Levodopa's water solubility and prolonging its circulation time, PEGylation reduces renal clearance and avoids immune detection. This modification improves penetration across the blood-brain barrier (BBB) through passive diffusion and the enhanced permeability and retention (EPR) effect. PEGylated nanoparticles encapsulating Levodopa offer improved stability and controlled drug release, thereby minimizing peripheral side effects. Recent studies highlight PEGylation's potential to increase the therapeutic efficacy of Levodopa by enhancing brain targeting and reducing dosing frequency.

v. Clinical Trials and Present Status of Levodopa, Carbidopa, and Their Combinations

Several key clinical trials have significantly contributed to the current understanding of Levodopa and its combinations. These studies have provided critical insights into the drug's efficacy, safety, and the management of Parkinson's disease.

a. ELLDOPA (Early vs. Later Levodopa Therapy in Parkinson's Disease

The ELLDOPA study aimed to determine whether early initiation of Levodopa therapy could influence the progression of Parkinson's disease. Patients were randomized to receive different doses of Carbidopa-Levodopa (25/100 mg, 25/250 mg, and 25/400 mg) over 40 weeks. The primary outcome measured was the change in the Unified Parkinson's Disease Rating Scale (UPDRS).[14]

b. STRIDE-PD (Stalevo Reduction in Dyskinesia Evaluation-Parkinson's Disease)

The STRIDE-PD trial investigated whether adding Entacapone, a catechol-O-methyltransferase (COMT) inhibitor, to Levodopa/Carbidopa (forming the combination drug Stalevo) could reduce the incidence of dyskinesia compared to standard Levodopa/Carbidopa therapy.[15]

c. CALM-PD (Comparison of Pramipexole and Levodopa in Early Parkinson's Disease)

The CALM-PD study compared the long-term effects of initiating treatment with Pramipexole, a dopamine agonist, versus Levodopa/Carbidopa. The primary objective was to determine the incidence of motor complications, such as dyskinesia, over a four-year period.[16]

The overview of Levodopa and its key combinations and current uses of Levodopa formulations were represented in table 1 & 2.

Table 1: Summary of Key Clinical Trials for Levodopa and Combinations.

Trial Name	Objective	Study Details	Findings
ELLDOPA	Assess whether early initiation of Levodopa therapy influences Parkinson's disease progression.	Patients received different doses of Carbidopa-Levodopa (25/100 mg, 25/250 mg, 25/400 mg) over 40 weeks.	Higher doses were associated with greater symptomatic relief but also a potential increase in dyskinesia over time. Early therapy did not conclusively alter disease progression.
STRIDE-PD	Investigate if adding Entacapone to Levodopa/Carbidopa (forming Stalevo) could reduce dyskinesia incidence.	Compared Stalevo with standard Levodopa/Carbidopa therapy.	Combination therapy provided some motor improvement but did not significantly reduce dyskinesia onset; some patients experienced earlier onset of dyskinesia.
CALM-PD	Compare long-term effects of Pramipexole versus Levodopa/Carbidopa in early Parkinson's disease.	Evaluated motor complications, like dyskinesia, over four years.	Levodopa/Carbidopa was more effective for motor control but associated with higher dyskinesia rates. Pramipexole led to fewer

			motor issues but more non-motor side effects.
IPX066 (Rytary)	Evaluate the efficacy of an extended-release Carbidopa-Levodopa formulation (Rytary) for symptom control.	Assessed reduction in "off" time and improvement in "on" time.	Rytary significantly reduced "off" time and increased "on" time without troublesome dyskinesia, providing better overall motor symptom control.
Inhaled Levodopa (Inbrija)	Provide rapid relief of motor fluctuations during "off" episodes in Parkinson's disease.	Inhaled formulation for quick symptom relief during "off" periods.	Inbrija provided rapid improvement in motor symptoms, with an onset of action within 10 minutes. Common side effects included cough and upper respiratory tract infections.

Table 2: **Current Clinical Uses of Levodopa Formulations**

Formulation	Usage	Example	Advantages	Challenges
Immediate-release tablets	Initial treatment and dose titration.	**Sinemet**	Rapid symptom control	Requires frequent dosing
Extended-release formulations	Sustained symptom control, reduces dosing frequency.	**Rytary, Stalevo**	Prolonged "on" time, reduced "off" time	Possible delayed onset of action, complex titration
Inhalation powders	Rapid management of "off" episodes.	**Inbrija**	Quick relief during "off" periods	Limited by upper respiratory side effects
Subcutaneous infusions	Continuous Levodopa delivery, reducing "off" time and motor fluctuations.	**Duopa** (Levodopa-Carbidopa intestinal gel)	Consistent plasma levels, reduced motor fluctuations	Invasive, requires pump management

Regulatory Status

Levodopa, in combination with Carbidopa or Benserazide, is approved by major regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of Parkinson's disease. These combinations are recommended as first-line therapies in clinical guidelines for symptomatic relief in PD patients. The regulatory status reflects the robust evidence base supporting Levodopa's efficacy and safety, although ongoing monitoring and post-marketing studies continue to inform best practices.

Challenges and Future Directions

Despite its efficacy, long-term Levodopa use is associated with motor complications such as dyskinesia and motor fluctuations. Research is ongoing to develop neuroprotective therapies that could slow disease progression and reduce the need for high doses of Levodopa. Promising areas include:

- **Neuroprotective agents**: Current studies are investigating drugs that could delay the onset or slow the progression of Parkinson's disease, potentially altering the course of the disease rather than just managing symptoms.
- **Combination therapies**: Research is exploring new combinations of Levodopa with other neuroprotective or symptomatic treatments to enhance efficacy and reduce side effects. These studies aim to provide a more comprehensive approach to PD management, addressing both motor and non-motor symptoms.
- **Personalized medicine**: The use of genetic and biomarker profiles to tailor Levodopa therapy to individual patients is an emerging field. Personalized medicine offers the potential for more targeted and effective treatments, optimizing therapeutic outcomes and minimizing adverse effects.

CONCLUSION

Levodopa, particularly in combination with Carbidopa, remains the most effective treatment for Parkinson's disease. Clinical trials have continually refined its use, offering valuable insights into its benefits and limitations. However, challenges such as managing motor complications and the need for disease-modifying therapies persist. The present status of Levodopa in clinical practice is robust, with ongoing research focused on enhancing its efficacy and minimizing side effects. The future of Levodopa therapy may involve advanced delivery systems and personalized medicine, potentially transforming the management of Parkinson's disease.

REFERENCES

1. Erro R, Stamelou M. The Motor Syndrome of Parkinson's Disease. In: Bhatia KP, Chaudhuri KR, Stamelou M, editors. *International Review of Neurobiology*. Academic Press, 2017; 132: 25-32. https://doi.org/10.1016/bs.irn.2017.01.004
2. Haddad F, Sawalha M, Khawaja Y, Najjar A, Karaman R. Dopamine and levodopa prodrugs for the treatment of Parkinson's disease. *Molecules*, 2017; 23(1): 40. https://doi.org/10.3390/molecules23010040
3. Lees A, Tolosa E, Stocchi F, Ferreira JJ, Rascol O, Antonini A, et al. Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approach. *npj Parkinson's Disease*, 2023; 15–24. https://doi.org/10.1038/s41531-023-00456-6

4. Yacoubian TA. IPX066: a new intermediate-and extended-release carbidopa-levodopa formulation. *Neurodegener Dis Manag*, 2013; 3(2): 123-131. https://doi.org/10.2217/nmt.13.4
5. Navon N. The Accordion Pill®: unique oral delivery to enhance pharmacokinetics and therapeutic benefit of challenging drugs. *Ther Deliv*., 2019; 10(7): 433-442. https://doi.org/10.4155/tde-2018-0067
6. Verhagen Metman L, Stover N, Chen C, Cowles VE, Sweeney M. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease. *Mov Disord*., 2015; 30(9): 1222-1228. https://doi.org/10.1002/mds.26219
7. Baek JS, Choo CC, Qian C, Tan NS, Shen Z, Loo SC. Multi-Drug-Loaded Microcapsules with Controlled Release for Management of Parkinson's Disease. *Small*, 2016; 12(27): 3712-3722. https://doi.org/10.1002/smll.201600067
8. Obaidat R, Al-Shar'i N, Tashtoush B, Athamneh T. Enhancement of levodopa stability when complexed with β-cyclodextrin in transdermal patches. *Pharm Dev Technol*., 2018; 23(10): 986-997. https://doi.org/10.1080/10837450.2016.1245319
9. Ramot Y, Nyska A, Adar L, Durlach C, Fishelovitch D, Sacco G, et al. ND0701, A Novel Formulation of Apomorphine for Subcutaneous Infusion: 28-Day Pharmacokinetic Study in Minipigs and a Phase I Study in Healthy Volunteers. *CNS Drugs*, 2018; 32(5): 443-454. https://doi.org/10.1007/s40263-018-0512-x
10. Saylam E, Akkaya Y, Ilhan E, Cesur S, Guler E, Sahin A, et al. Levodopa-Loaded 3D-Printed Poly (Lactic) Acid/Chitosan Neural Tissue Scaffold as a Promising Drug Delivery System for the Treatment of Parkinson's Disease. *Appl Sci*., 2021; 11(22): 10727. https://doi.org/10.3390/app112210727
11. Teixeira MI, Lopes CM, Amaral MH, Costa PC. Surface-modified lipid nanocarriers for crossing the blood-brain barrier (BBB): A current overview of active targeting in brain diseases. *Colloids Surf B Biointerfaces*, 2023; 221: 112999. https://doi.org/10.1016/j.colsurfb.2022.112999
12. Jagaran K, Singh M. Lipid Nanoparticles: Promising Treatment Approach for Parkinson's Disease. *Int J Mol Sci*., 2022; 23(16): 9361. https://doi.org/10.3390/ijms23169361
13. Cai H, Liu D, Xue WW, Ma L, Xie HT, Ning K. Lipid-based nanoparticles for drug delivery in Parkinson's disease. *Transl Neurosci*., 2024; 15(1): 20220359. https://doi.org/10.1515/tnsci-2022-0359
14. Bressman S, Saunders-Pullman R. When to Start Levodopa Therapy for Parkinson's Disease. *N Engl J Med*., 2019; 380: 389-390. https://doi.org/10.1056/NEJMc1807849

15. Olanow CW, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. *Mov Disord*, 2013; 28(8): 1064-1071. https://doi.org/10.1002/mds.25437
16. Parkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. *Clin Neuropharmacol*, 2000; 23(1): 34-44. https://doi.org/10.1097/00002826-200001000-00007